STOCKHOLM, Sweden--(BUSINESS WIRE)--The biopharma company Biovitrum (STO:BVT), listed on the Stockholm Stock Exchange since September 15, 2006, has initiated a clinical Phase II study with the candidate drug BVT.28949, a 5-HT2A antagonist for the treatment glaucoma. The results are expected to be available midyear of 2007.
